StockData

MacroGenics vs Precigen

MGNX and PGEN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How MGNX and PGEN compare

Precigen is the larger company, worth 12 times as much as MacroGenics ($1.5B against $131M).

MacroGenics scores higher on the StockData Score (5 against 2 for Precigen), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricMGNXPGEN
Size and price
Market cap$131M$1.5B
Share price$2.05$4.29
Change, 1 year36.7%−11.5%
Change, 5 years−89.1%11.1%
Beta (5Y)0.531.20
Employees29320
StockData Score
Total score5 (better)2
Valuation score00
Growth score1 (better)0
Performance score3 (better)0
Health score12 (better)
Dividend score00
Valuation
P/S0.8×–
P/B3.0× (better)35.2×
FCF yield−50.2%−7.5% (better)
Growth
Revenue growth (TTM)11.7%–
Revenue growth, 5Y average7.3% (better)−21.3%
Profitability
Operating margin−24.3%–
Net margin−8.7%–
FCF margin−39.1%–
Return on equity−32.6% (better)−4640%
Financial health
Debt / equity–2.15
Interest coverage−2.4×–
Current ratio2.964.58 (better)
Altman Z-score−4.02 (better)−11.14
Piotroski F-score4 (better)2
Dividends and buybacks
Buyback yield–0.00%
Shareholder yield0.00%0.00%
Ownership
Held by institutions76.4%39.2%
Held by insiders6.2%44.9%
Insider net buying, 12 months−$129K (better)−$32.5M
Superinvestors holding–1
Short interest, % of float8.3%22.8%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.